Interpace Diagnostics Announces Agreement with America's Choice Provider Network to Cover All of the Company's Molecular Tests for Thyroid and Pancreatic Cancer

Mar 1, 2016

Interpace Diagnostics Receives Medicare Coverage For Its ThyraMIR™ Micro RNA Gene Expression Classifer

Feb 17, 2016

PancraGen® Clinical Utility Study Published in Diagnostic Pathology

Jan 28, 2016

Interpace Diagnostics Announces New Medicare Local Coverage Determination for Molecular Testing of Pancreatic Cysts

Jan 20, 2016

Interpace Diagnostics' New Molecular Test for Thyroid Nodules Now Available Through LabCorp

Jan 12, 2016

Interpace Diagnostics Group Begins Trading on NASDAQ

Dec 23, 2015